 Heather Moore
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 13 | 2026 | 2380 | 1.870 |
Why?
| | Estrogen Receptor alpha | 4 | 2026 | 151 | 1.430 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 46 | 0.910 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2026 | 881 | 0.790 |
Why?
| | Oxazepines | 2 | 2019 | 5 | 0.760 |
Why?
| | Imidazoles | 2 | 2019 | 247 | 0.680 |
Why?
| | Biomarkers, Tumor | 1 | 2026 | 1320 | 0.570 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2014 | 79 | 0.450 |
Why?
| | Receptors, Estrogen | 6 | 2024 | 401 | 0.360 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 264 | 0.350 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3539 | 0.320 |
Why?
| | Carbolines | 3 | 2024 | 35 | 0.300 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2207 | 0.280 |
Why?
| | Biomarkers | 2 | 2019 | 4282 | 0.280 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2026 | 192 | 0.260 |
Why?
| | Cell Lineage | 2 | 2026 | 377 | 0.250 |
Why?
| | Mutation | 4 | 2026 | 4071 | 0.240 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2026 | 9 | 0.240 |
Why?
| | Forkhead Box Protein M1 | 1 | 2026 | 11 | 0.240 |
Why?
| | Neoplasm Metastasis | 2 | 2026 | 688 | 0.230 |
Why?
| | Piperazines | 2 | 2024 | 375 | 0.210 |
Why?
| | Pyridines | 3 | 2024 | 608 | 0.210 |
Why?
| | Glucuronosyltransferase | 1 | 2024 | 18 | 0.210 |
Why?
| | Patient Discharge | 3 | 2022 | 991 | 0.200 |
Why?
| | Signal Transduction | 4 | 2026 | 5208 | 0.180 |
Why?
| | Female | 18 | 2026 | 78636 | 0.180 |
Why?
| | Respiration, Artificial | 2 | 2017 | 713 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2026 | 1442 | 0.150 |
Why?
| | Paclitaxel | 1 | 2019 | 256 | 0.140 |
Why?
| | Humans | 20 | 2026 | 145140 | 0.130 |
Why?
| | Continuity of Patient Care | 2 | 2017 | 296 | 0.130 |
Why?
| | Chemokines, CXC | 1 | 2017 | 68 | 0.130 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2014 | 55 | 0.120 |
Why?
| | Ventilator Weaning | 1 | 2016 | 40 | 0.120 |
Why?
| | Hedgehog Proteins | 1 | 2017 | 200 | 0.110 |
Why?
| | Airway Management | 1 | 2016 | 81 | 0.110 |
Why?
| | Simulation Training | 1 | 2017 | 135 | 0.110 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 84 | 0.110 |
Why?
| | Laryngoscopy | 1 | 2016 | 119 | 0.110 |
Why?
| | Animals | 7 | 2026 | 37952 | 0.100 |
Why?
| | Tracheostomy | 1 | 2016 | 142 | 0.100 |
Why?
| | Receptor, Notch1 | 1 | 2014 | 63 | 0.100 |
Why?
| | Preoperative Care | 1 | 2016 | 380 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2662 | 0.100 |
Why?
| | Aromatase Inhibitors | 2 | 2024 | 78 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1958 | 0.090 |
Why?
| | Mice, SCID | 1 | 2013 | 369 | 0.090 |
Why?
| | Carcinoma | 1 | 2014 | 224 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 333 | 0.090 |
Why?
| | Ultrasonography | 1 | 2016 | 784 | 0.090 |
Why?
| | Quality Improvement | 2 | 2017 | 1293 | 0.090 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 219 | 0.080 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 218 | 0.080 |
Why?
| | Postmenopause | 2 | 2023 | 391 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1188 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 1795 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 696 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1348 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2017 | 690 | 0.070 |
Why?
| | Phosphorylation | 1 | 2013 | 1706 | 0.070 |
Why?
| | Caregivers | 1 | 2017 | 1070 | 0.070 |
Why?
| | Cell Movement | 1 | 2013 | 959 | 0.070 |
Why?
| | Mice | 4 | 2025 | 18303 | 0.070 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2023 | 4 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2023 | 117 | 0.050 |
Why?
| | Cinnamates | 1 | 2022 | 12 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2022 | 37 | 0.050 |
Why?
| | Gene Frequency | 1 | 2024 | 484 | 0.050 |
Why?
| | Middle Aged | 5 | 2024 | 36126 | 0.050 |
Why?
| | Indazoles | 1 | 2022 | 83 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 216 | 0.050 |
Why?
| | Haplotypes | 1 | 2024 | 498 | 0.040 |
Why?
| | Tamoxifen | 1 | 2022 | 191 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 343 | 0.040 |
Why?
| | Human Genome Project | 1 | 2001 | 15 | 0.040 |
Why?
| | Progesterone | 1 | 2022 | 214 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 614 | 0.040 |
Why?
| | Aged | 4 | 2024 | 26096 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2022 | 243 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 664 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 465 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 367 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 210 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1844 | 0.040 |
Why?
| | Genome, Human | 1 | 2001 | 419 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2001 | 776 | 0.030 |
Why?
| | Adult | 4 | 2024 | 40665 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2025 | 2504 | 0.030 |
Why?
| | Transitional Care | 1 | 2017 | 45 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 117 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2022 | 775 | 0.030 |
Why?
| | Anilides | 1 | 2017 | 84 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1371 | 0.030 |
Why?
| | Up-Regulation | 1 | 2017 | 846 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2014 | 116 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2014 | 139 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 337 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2019 | 11741 | 0.020 |
Why?
| | Male | 5 | 2024 | 72664 | 0.020 |
Why?
| | Infant | 2 | 2017 | 10060 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 739 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1506 | 0.020 |
Why?
| | Child, Preschool | 2 | 2017 | 11835 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1177 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1995 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1159 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1713 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2377 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4142 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1244 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3410 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5411 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2588 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3740 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8318 | 0.020 |
Why?
| | Child | 2 | 2017 | 22670 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5972 | 0.010 |
Why?
| | Lung | 1 | 2017 | 4101 | 0.010 |
Why?
| | Chromosome Banding | 1 | 2001 | 17 | 0.010 |
Why?
| | Physical Chromosome Mapping | 1 | 2001 | 20 | 0.010 |
Why?
| | Neoplasms | 1 | 2017 | 2900 | 0.010 |
Why?
| | Pseudogenes | 1 | 2001 | 20 | 0.010 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2001 | 19 | 0.010 |
Why?
| | Consensus Sequence | 1 | 2001 | 73 | 0.010 |
Why?
| | DNA, Intergenic | 1 | 2001 | 26 | 0.010 |
Why?
| | Gene Duplication | 1 | 2001 | 66 | 0.010 |
Why?
| | Retroelements | 1 | 2001 | 50 | 0.010 |
Why?
| | Genes | 1 | 2001 | 226 | 0.010 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2001 | 117 | 0.010 |
Why?
| | CpG Islands | 1 | 2001 | 161 | 0.010 |
Why?
| | Introns | 1 | 2001 | 253 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2001 | 504 | 0.010 |
Why?
| | Species Specificity | 1 | 2001 | 545 | 0.010 |
Why?
| | Exons | 1 | 2001 | 363 | 0.010 |
Why?
| | United States | 1 | 2017 | 16065 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 14176 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2001 | 490 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 22479 | 0.010 |
Why?
| | Computational Biology | 1 | 2001 | 669 | 0.010 |
Why?
| | Genetic Variation | 1 | 2001 | 967 | 0.010 |
Why?
| | Databases, Factual | 1 | 2001 | 1488 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 1022 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2001 | 2136 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1845 | 0.010 |
Why?
| | Phenotype | 1 | 2001 | 3138 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|